Holen Sie sich die Stockscreener-App
13.56
2.23%
-0.32
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia
Trinity Delta Lighthouse: HUTCHMED - Vox Markets
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - finance.yahoo.com
HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - marketbeat.com
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - Benzinga
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - marketbeat.com
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - marketbeat.com
HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com
HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView
HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan
HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com
REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - finance.yahoo.com
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat
Sea Limited Sponsored ADR (SE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView
HCM Stock Price, Quote & Chart - ChartMill
Sea Limited Sponsored ADR (SE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
0J7G Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView
Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan
RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire
HUTCHMED analyst targets stay high, shares trade well below consensus - ad-hoc-news.de
HUTCHMED Announces Phase III China Data from ESLIM-02 Study of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia - aastocks.com
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewswire Inc.
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - Barchart.com
HUTCHMED (Nasdaq: HCM) files AIM block for 43,616,756 shares - Stock Titan
BeOne Medicines Ltd.Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock? - finance.yahoo.com
HCMHUTCHMED (China) Limited ADR Stock Price and Quote - Finviz
HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan
HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com
HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com
New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewswire
HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
0.33%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):